Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SymBio Initiates Japanese Phase II Trial for TREAKISYM®

Published: Friday, May 10, 2013
Last Updated: Friday, May 10, 2013
Bookmark and Share
Company has commenced enrollment for bendamustine in CLL patients.

SymBio Pharmaceuticals Limited has announced that it has commenced enrollment in a Phase 2 clinical trial in Japan for bendamustine hydrochloride (Brand Name: TREAKISYM®) in chronic lymphocytic leukemia (CLL) patients.

In partnership with Eisai Co., Ltd., SymBio received marketing approval for TREAKISYM® (SyB L-0501) in October, 2010, to treat Japanese patients with relapsed/refractory (r/r) low-grade non-Hodgkin’s lymphoma (LG-NHL) and mantle cell lymphoma (MCL).

CLL is a cancer of the blood characterized by the progressive accumulation of functionally incompetent lymphocytes, a type of white blood cell produced by the bone marrow and organs of the lymphatic system.

The number of CLL patients in Japan is estimated to be around 2,000. In the US and EU, bendamustine has been approved for the treatment of CLL where the disease accounts for an estimated 30% of all leukemia cases.

Due to the lack of effective therapies in Japan, CLL patients are seriously underserved and a high unmet medical need exists for the development of an effective alternative therapy.

In Japan, the Ministry of Health, Labour and Welfare (MHLW) Working Group has designated TREAKISYM® as a prioritized unapproved drug having high potential to address the lack of an effective therapy in CLL. TREAKISYM® was designated by MHLW as an orphan drug for the CLL indication in June, 2012.

SymBio has initiated several phase 2 trials for SyB L-0501. The Company continues to pursue other indications for TREAKISYM® in the hematology space as nimbly as possible in order to maximize the potential of TREAKISYM® and address other high unmet medical needs in patients.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
NCI Collaborates with Multiple Myeloma Research Foundation
NCI collaborates with MMRF to incorporate genomic and clinical data into NCI Genomic Data Commons database.
Epigenetic Clock Predicts Life Expectancy
New research finds 5 percent of population ages faster, faces shorter lifespan.
Modified Yeast Shows Plant Response to Key Hormone
Researchers have developed a toolkit based on modified yeast to determine plant responses to auxin.
Death-or-Repair Switch Protein Identified
Researchers have identified a protein that plays a key role in the decision process of cell damage repair or cellular suicide.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Regulatory RNA Essential to DNA Damage Response
Researchers discover a tumour suppressor is stabilized by an RNA molecule, which helps cells respond to DNA damage.
Wearable Microscope Can Measure Fluorescent Dyes Through Skin
UCLA research could make monitoring disease biomarkers easier and more cost-effective.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Genetic Impact of Endurance Training
Research has found that endurance training changes genetic activity in thousands of genes, giving rise to large number of altered RNA variants.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!